Summary
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
History
Founded in 1925 in Tokyo's Kasumigaseki district, Seikagaku has grown to become a global leader in healthcare solutions. Through more than eighty years of devoted research and development, Seikagaku has become a trusted and respected name in pharmaceuticals, medical devices, and healthcare services.
Mission
Seikagaku is committed to providing the highest-quality medicines, devices, and services to patients around the world. Our commitment to improving healthcare outcomes is fueled by our unyielding dedication to patient safety and excellence in clinical outcomes.
Vision
Seikagaku is dedicated to making a positive impact on the health and overall well-being of the patients we serve. We strive to bring innovative solutions to the healthcare community that are cost effective, safe and effective.
Key Team
Yuji Shimojima (Exec. VP of Quality Compliance & Medical Affairs)
Mikako Torii (Exec. VP, Head of Corp. Staff and Audit & Supervisory Board Member)
Mr. Yosuke Funakoshi (Exec. VP of R&D and Director)
Masayuki Ito (Exec. VP and Head of Takahagi Plant & Production)
Recognition and Awards
Seikagaku has been the recipient of numerous awards and accolades, including the prestigious Nikkei Global Innovation Award, as well as the Los Angeles Business Journal’s Best-Managed Companies Award. Seikagaku has been named to the IAOP’s Global Outsourcing 100 list four times since 2009.
References
